Incyte Corporation
INCY
Peringkat dalam Saham
#1001
Incyte Corporation is a biopharmaceutical firm engaged in the research,... Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Harga Saham
$116.38
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$23.59B
Perubahan (1 hari)
2.76%
Perubahan (1 tahun)
33.31%
Negara
US
Perdagangan Incyte Corporation (INCY)
Kategori
Healthcare
Rasio P/E untuk Incyte Corporation (INCY)
Rasio P/E per October 2026 TTM: 13.72
Menurut laporan keuangan dan harga saham terbaru dari Incyte Corporation, rasio P/E saat ini (TTM) adalah 13.72. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar 438.60.
Riwayat rasio P/E untuk Incyte Corporation dari 2000 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 13.72 | -8.39% |
| 2025 | 14.98 | -96.58% |
| 2024 | 438.60 | 1,766.66% |
| 2023 | 23.50 | -55.11% |
| 2022 | 52.34 | 206.89% |
| 2021 | 17.06 | -126.59% |
| 2020 | -64.15 | -252.76% |
| 2019 | 41.99 | -65.96% |
| 2018 | 123.35 | -299.34% |
| 2017 | -61.88 | -134.23% |
| 2016 | 180.75 | -93.94% |
| 2015 | 2.98K | -1,282.99% |
| 2014 | -252.10 | 178.98% |
| 2013 | -90.37 | 85.84% |
| 2012 | -48.63 | 382.05% |
| 2011 | -10.09 | -84.05% |
| 2010 | -63.25 | 1,328.89% |
| 2009 | -4.43 | 132.73% |
| 2008 | -1.90 | -80.47% |
| 2007 | -9.74 | 47.58% |
| 2006 | -6.60 | 52.82% |
| 2005 | -4.32 | -4.45% |
| 2004 | -4.52 | 54.10% |
| 2003 | -2.93 | 30.60% |
| 2002 | -2.25 | -68.03% |
| 2001 | -7.02 | -86.72% |
| 2000 | -52.88 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 28.78 | 109.73% |
US
|
|
| -28.36 | -306.65% |
US
|
|
| -24.57 | -279.02% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 121.01% |
NL
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.